Amphastar Pharmaceuticals Inc (AMPH) Stake Increased by Millennium Management LLC

Millennium Management LLC lifted its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 1,746.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 293,672 shares of the company’s stock after buying an additional 277,771 shares during the quarter. Millennium Management LLC’s holdings in Amphastar Pharmaceuticals were worth $5,650,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in AMPH. Dimensional Fund Advisors LP grew its position in shares of Amphastar Pharmaceuticals by 17.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after buying an additional 226,271 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Amphastar Pharmaceuticals by 156.1% during the fourth quarter. Wells Fargo & Company MN now owns 176,323 shares of the company’s stock worth $3,392,000 after buying an additional 107,486 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Amphastar Pharmaceuticals by 148.9% during the fourth quarter. Alliancebernstein L.P. now owns 113,520 shares of the company’s stock worth $2,184,000 after buying an additional 67,920 shares in the last quarter. Arizona State Retirement System grew its position in shares of Amphastar Pharmaceuticals by 221.6% during the fourth quarter. Arizona State Retirement System now owns 59,499 shares of the company’s stock worth $1,145,000 after buying an additional 40,999 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $400,000. 44.50% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of AMPH opened at $19.18 on Tuesday. Amphastar Pharmaceuticals Inc has a 12-month low of $13.15 and a 12-month high of $20.45. The firm has a market cap of $878.81, a P/E ratio of 50.47, a PEG ratio of 1.35 and a beta of 1.41. The company has a current ratio of 2.79, a quick ratio of 1.85 and a debt-to-equity ratio of 0.12.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Monday, March 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.03. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The firm had revenue of $60.40 million for the quarter, compared to analysts’ expectations of $60.62 million. During the same period last year, the business posted $0.01 earnings per share. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. analysts predict that Amphastar Pharmaceuticals Inc will post 0.63 EPS for the current fiscal year.

A number of analysts have recently weighed in on AMPH shares. Wells Fargo reissued a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. Piper Jaffray restated a “buy” rating and set a $26.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Tuesday, January 30th. Needham & Company LLC restated a “buy” rating and set a $24.00 price objective (up from $23.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $21.33.

In other Amphastar Pharmaceuticals news, General Counsel Jason B. Shandell sold 8,661 shares of the firm’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $19.26, for a total value of $166,810.86. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO William J. Peters sold 19,801 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total value of $398,000.10. The disclosure for this sale can be found here. Insiders have sold 84,387 shares of company stock worth $1,659,763 over the last 90 days. 11.10% of the stock is currently owned by company insiders.

WARNING: “Amphastar Pharmaceuticals Inc (AMPH) Stake Increased by Millennium Management LLC” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/17/amphastar-pharmaceuticals-inc-amph-stake-increased-by-millennium-management-llc.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply